Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer.

Tetracore, Inc. company's FDA-approved Redline lab test can distinguish anthrax bacteria from similar microorganisms. Other bioterrorism countermeasures the firm offers include the BioThreat Alert testing kit used by first responders to detect various biological toxins including botulinum toxin (botulism) and staphylococcus aureus enterotoxin B (SEB). Tetracore also sells veterinary diagnostic (VetAlert) tests for foot-and-mouth disease, West Nile, and other diseases, and it markets antibodies (proteins) for use by research labs.

The revolution in genomics and proteomics spawned by the human genome project is providing a steady stream of protein therapeutic candidates. Many of these proteins require enhancements in their pharmacokinetic properties in order to be clinically effective because of inherent limitations of proteins as drugs. Advanced Proteome Therapeutics has initiated a program that is broadly applicable to proteins. It builds on a technology platform developed over twenty years of targeting proteins for site-selective modification and addresses issues which limit therapeutic utilization of promising proteins.The Company’s laboratories are located at the BioSquare Innovation and Discovery Center on the campus of the Boston University School of Medicine. Its scientists are engaged in research and development applying leading edge chemical and biochemical methodologies to commercially viable proteins. The technology is applicable to the generation of a variety of protein products including protein therapeutics, protein diagnostics and high value reagents for research.

New Energy Technologies, Inc. was founded in 1998 and is based in Burtonsville, Maryland. New Energy Technologies, Inc., through its subsidiaries, engages in the identification, acquisition, development, and commercialization of alternative energy technologies. It focuses on the development of MotionPower, a technology for capturing the kinetic energy of moving vehicles in order to use this captured energy to generate electricity; and SolarWindow, a technology that enables transparent glass windows to generate electricity by coating their glass surfaces with small solar cells. The company was formerly known as Octillion Corp. and changed its name to New Energy Technologies, Inc. in January 2009.

Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California. Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan.

Falcon Pharmaceuticals, Ltd. company specializes in making generic equivalents of ophthalmic drugs that treat a range of eye conditions, as well as otic (ear) and nasal ailments. Its lead product, Timolol GFS, is a generic equivalent of Merck's glaucoma treatment Timoptic-XE gel. Falcon Pharmaceuticals company also offers anti-infective, steroid, anti-viral, anti-allergy, and anesthetic pharmaceutical products without the markup typically associated with brand names. Falcon Pharmaceuticals is a subsidiary of eye care products company Alcon.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

AstraZeneca France does its bit to help its parent, global pharmaceutical powerhouse AstraZeneca, fight diseases from A to Z. In addition to its headquarters at Reuil Malmaison, the company operates an R&D facility for cancer treatments and packaging in Reims. The plant, which produces cancer as well as cardiovascular drugs, sends about a third of its product to Italy, the rest to North Africa and Portugal. The company's Dunkirk production plant makes Pulmicort, Symbicort, Mopral, and INexium in its chemical unit, while the pharmaceutical unit makes Bricanyl and Turbuhaler. Dunkirk ships its finished products to the US. In all AstraZeneca France, which was formed in 1975, makes and ships about 40 drugs.

Shionogi & Co. wants to kill it like a shinobi (i.e. ninja) in the night. The Japanese drug firm is a leading maker of antibiotics in its home country, with a full lineup of oral and injectable anti-infectives. It has been expanding its pipeline and its portfolio of marketed products to encompass other therapeutic areas as well, with programs in metabolic conditions and pain management. Through partnerships with large global firms, it owns Japanese market rights to some big name drugs, including AstraZeneca's blood pressure drug Crestor (which Shionogi helped develop); Purdue Pharma's pain therapy OxyContin; and Merck & Co. allergy medication Claritin.

Hycor Biomedical makes medical diagnostic products and sells them in the US and abroad. Hycor's KOVA urinalysis system, which enables labs to perform uniform microscopic analyses of urine specimens, is used in applications including personnel safety and pregnancy testing. Hycor company also produces allergy diagnosis products and kits for detecting rheumatoid arthritis and other autoimmune diseases. Its products are sold by distributors and the company's sales force. Hycor Biomedical is a subsidiary of life sciences company Agilent.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.